Literature DB >> 18922483

Pharmacodynamics and pharmacokinetics of antibacterial drugs in the management of febrile neutropenia.

Olivier Lortholary1, Agnès Lefort, Michel Tod, Anne-Marie Chomat, Clémence Darras-Joly, Catherine Cordonnier.   

Abstract

We review experimental and clinical data on the pharmacokinetics and pharmacodynamics of antibacterial drugs in febrile neutropenic hosts. Since major pharmacokinetic changes have been reported for various classes of antibiotics in these patients, we advocate the need for adequate initial dosing regimens in all cases. Monitoring drug serum concentrations is mandatory for aminoglycosides and glycopeptides, and special attention should be paid to the dosing frequency of the short half-life beta-lactams to optimise the management of febrile neutropenia, especially in patients with severe sepsis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18922483     DOI: 10.1016/S1473-3099(08)70228-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  20 in total

1.  Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.

Authors:  Fekade Bruck Sime; Michael S Roberts; Morgyn S Warner; Uwe Hahn; Thomas A Robertson; Sue Yeend; Andy Phay; Sheila Lehman; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2014-03-31       Impact factor: 5.191

2.  The role of antibiotic stewardship in limiting antibacterial resistance among hematology patients.

Authors:  Inge C Gyssens; Winfried V Kern; David M Livermore
Journal:  Haematologica       Date:  2013-12       Impact factor: 9.941

3.  High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function.

Authors:  F Lamoth; T Buclin; A Pascual; S Vora; S Bolay; L A Decosterd; T Calandra; O Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-07-12       Impact factor: 5.191

Review 4.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

5.  Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.

Authors:  Fekade Bruck Sime; Uwe Hahn; Morgyn S Warner; Ing Soo Tiong; Michael S Roberts; Jeffrey Lipman; Sandra L Peake; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Antibiotic therapy in hematological neutropenic patients: what is the news?

Authors:  F Pea
Journal:  Leuk Suppl       Date:  2012-08-09

Review 7.  Implications of augmented renal clearance in critically ill patients.

Authors:  Andrew A Udy; Jason A Roberts; Jeffrey Lipman
Journal:  Nat Rev Nephrol       Date:  2011-07-19       Impact factor: 28.314

8.  Drug fever after cancer chemotherapy is most commonly observed on posttreatment days 3 and 4.

Authors:  Daiki Ogawara; Minoru Fukuda; Shiro Ueno; Yoshihiro Ohue; Shinnosuke Takemoto; Kosuke Mizoguchi; Katsumi Nakatomi; Yoichi Nakamura; Yasushi Obase; Takuya Honda; Kazuhiro Tsukamoto; Kazuto Ashizawa; Mikio Oka; Shigeru Kohno
Journal:  Support Care Cancer       Date:  2015-06-25       Impact factor: 3.603

9.  Teicoplanin dosing strategy for treatment of Staphylococcus aureus in Korean patients with neutropenic fever.

Authors:  Byung-Jin Ahn; Dong-Seok Yim; Dong-Gun Lee; Jae-Cheol Kwon; Si-Hyun Kim; Su-Mi Choi
Journal:  Yonsei Med J       Date:  2011-07       Impact factor: 2.759

10.  Fitness Landscape of the Immune Compromised Favors the Emergence of Antibiotic Resistance.

Authors:  Elisa Margolis; Jason W Rosch
Journal:  ACS Infect Dis       Date:  2018-08-02       Impact factor: 5.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.